T1	p 61 69	bestatin
T2	p 73 114	acute nonlymphocytic leukemia in adults .
T3	p 419 461	adult acute nonlymphocytic leukemia ( ANLL
T4	p 628 659	101 eligible cases ( bestatin :
T5	p 931 949	15-49 yr age group
T6	p 955 971	the 50-65 yr age
T7	p 1151 1167	elderly patients
T8	p 1192 1193	.
T9	i 37 55	chemoimmunotherapy
T10	i 61 69	bestatin
T11	i 121 171	immunomodulating agent , bestatin ( INN : Ubenimex
T12	i 337 414	bestatin immunotherapy in combination with remission maintenance chemotherapy
T13	i 552 566	bestatin group
T14	i 608 615	control
T15	i 649 657	bestatin
T16	i 694 695	;
T17	i 700 708	bestatin
T18	i 1008 1016	Bestatin
T19	o 79 93	nonlymphocytic
T20	o 724 740	longer remission
T21	o 803 813	survival .
T22	o 826 851	prolongation of remission
T23	o 1114 1122	survival